Women who give up weight-loss jabs for pregnancy can suffer harmful weight gain

When women taking weight loss jabs stop their use because of pregnancy, the rebound weight gain brings health risks for their babies. Women who paused the injections before or shortly after conceiving were more likely to gain excess weight in pregnancy, a study has found. This made them more likely to develop diabetes or high […]

People who stop using Mounjaro tend to regain weight and lose other health benefits, says study

Improvements such as reduced ‘bad’ cholesterol and lower blood pressure go into reverse upon stopping weight-loss jabsPeople who stop using the weight-loss jab Mounjaro not only tend to regain weight, but experience a reversal in other health improvements too, research suggests.Mounjaro, which contains the active ingredient tirzepatide, has become a popular medication for weight loss, with studies suggesting that it can help people lose an average of 20% of their body weight after 72 weeks of treatment. Continue reading…

STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! We’re closing in on CMS’s deadline for 2027 Medicare-negotiated drug prices. Plus, we see a break from precedent in how the FDA selects priority review vouchers, and more.  Can a GLP-1 drug slow Alzheimer’s […]

Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in

Eli Lilly LLY briefly crossed the $1 trillion market cap on Nov. 21, 2025 — becoming the first-ever health-care company to join the elite group mainly dominated by tech giants, as mentioned on CNBC. Shares touched around $1,059 on the day. GLP-1 &GIP Leadership Fuels Rally The stock has surged 36.2% this year, mainly backed by […]

NVO US

NVO US Novo Nordisk A/S Sponsored ADR Class B BATS:NVO A3MInvestments The decline in Novo Nordisk shares is not the result of a single factor, but rather the result of a complex set of fundamental issues: weakening financial performance, loss of competitive advantage in key products, and increased strategic risks. While negative data on Eli […]